Postnatal Cytomegalovirus Infection: a Pilot Comparative Effectiveness Study of Transfusion Safety Using Leukoreduced-only Transfusion Strategy

Overview

Journal Transfusion

Specialty Hematology

Date 2016 Apr 16

PMID 27080192

Citations 7

Authors

Meghan Delaney

Dennis Mayock

Andrea Knezevic

Colette Norby-Slycord

Elizabeth Kleine

Ravi Patel

Kirk Easley

Cassandra Josephson

Affiliations

Soon will be listed here.

Abstract

Background: The optimal mitigation strategy to prevent transfusion transmission of cytomegalovirus (TT-CMV) in preterm very low birthweight infants remains debated. Hospitals caring for this patient population have varied practices.

Study Design And Methods: A prospective observational comparative effectiveness pilot study was conducted to determine the feasibility for a larger study. The pilot was carried out at hospitals using a leukoreduction (LR)-only transfusion strategy. Specimen and data collection for this study was performed in a similar approach to a study completed at Emory University that employed the CMV-seronegative plus LR approach. All testing was performed at one laboratory. The rates of TT-CMV using the two transfusion strategies were compared.

Results: Zero incidence of TT-CMV was detected in infants (n = 20) transfused with LR-only blood (0/8; 95% confidence interval [CI], 0-25.3%) and is consistent with the previously reported zero incidence of TT-CMV finding in a cohort of infants transfused with CMV-negative plus LR blood (0/310; 95% CI, 0%-0.9%). The seroprevalence rate among enrolled mothers (n = 17) was 60%. Forty percent of those infants (8/20) received 43 transfusions; five were transfused with one or more CMV-seropositive blood components. One infant had tested positive for CMV before receiving blood transfusions; the infant's mother was CMV immunoglobulin (Ig)G positive and IgM negative.

Conclusions: Using the LR-only transfusion approach, zero cases of TT-CMV were detected in this pilot study. A larger study is needed to reliably determine the most effective strategy for prevention of TT-CMV in this population.

Citing Articles

New frontiers in neonatal red blood cell transfusion research.

Stark C, Juul S J Perinatol. 2023; 43(11):1349-1356.

PMID: 37667005 DOI: 10.1038/s41372-023-01757-7.

Prevention of human milk-acquired cytomegalovirus infection in very-low-birth-weight infants.

Chung M, Sung H, Jung E, Lee B, Kim K, Kim E BMC Pediatr. 2023; 23(1):244.

PMID: 37202724 PMC: 10193732. DOI: 10.1186/s12887-023-04044-8.

Transfusion in Neonatal Patients: Review of Evidence-Based Guidelines.

Zerra P, Josephson C Clin Lab Med. 2021; 41(1):15-34.

PMID: 33494882 PMC: 9015674. DOI: 10.1016/j.cll.2020.10.002.

Infectious complications in neonatal transfusion: Narrative review and personal contribution.

Bianchi M, Orlando N, Valentini C, Papacci P, Vento G, Teofili L Transfus Apher Sci. 2020; 59(5):102951.

PMID: 32972859 PMC: 7492833. DOI: 10.1016/j.transci.2020.102951.

Impact of breast milk-acquired cytomegalovirus infection in premature infants: Pathogenesis, prevention, and clinical consequences?.

Osterholm E, Schleiss M Rev Med Virol. 2020; 30(6):1-11.

PMID: 32662174 PMC: 8173712. DOI: 10.1002/rmv.2117.

References

Ziemann M, Krueger S, Maier A, Unmack A, Goerg S, Hennig H . High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion. 2007; 47(11):1972-83. DOI: 10.1111/j.1537-2995.2007.01420.x. View

Gilbert G, Hayes K, Hudson I, James J . Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet. 1989; 1(8649):1228-31. DOI: 10.1016/s0140-6736(89)92330-1. View

Josephson C, Castillejo M, Caliendo A, Waller E, Zimring J, Easley K . Prevention of transfusion-transmitted cytomegalovirus in low-birth weight infants (≤1500 g) using cytomegalovirus-seronegative and leukoreduced transfusions. Transfus Med Rev. 2011; 25(2):125-32. PMC: 4793905. DOI: 10.1016/j.tmrv.2010.11.004. View

Josephson C, Caliendo A, Easley K, Knezevic A, Shenvi N, Hinkes M . Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr. 2014; 168(11):1054-62. PMC: 4392178. DOI: 10.1001/jamapediatrics.2014.1360. View

Nichols W, Price T, Gooley T, Corey L, Boeckh M . Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003; 101(10):4195-200. DOI: 10.1182/blood-2002-10-3143. View

Wu Y, Zou S, Cable R, Dorsey K, Tang Y, Hapip C . Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion. 2009; 50(4):776-86. DOI: 10.1111/j.1537-2995.2009.02486.x. View

Rice G, Schrier R, Oldstone M . Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci U S A. 1984; 81(19):6134-8. PMC: 391874. DOI: 10.1073/pnas.81.19.6134. View

Mainou M, Alahdab F, Tobian A, Asi N, Mohammed K, Murad M . Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis. Transfusion. 2016; 56(6 Pt 2):1569-80. DOI: 10.1111/trf.13478. View

Drew W, Tegtmeier G, Alter H, Laycock M, Miner R, Busch M . Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion. 2003; 43(3):309-13. DOI: 10.1046/j.1537-2995.2003.00337.x. View

10.

Smith D, Lu Q, Yuan S, Goldfinger D, Fernando L, Ziman A . Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative. Vox Sang. 2009; 98(1):29-36. DOI: 10.1111/j.1423-0410.2009.01228.x. View

11.

Bowden R, Slichter S, Sayers M, Weisdorf D, Cays M, Schoch G . A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995; 86(9):3598-603. View

12.

Mosca F, Pugni L, Barbi M, Binda S . Transmission of cytomegalovirus. Lancet. 2001; 357(9270):1800. DOI: 10.1016/S0140-6736(00)04914-X. View

13.

Vamvakas E . Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 2005; 19(3):181-99. DOI: 10.1016/j.tmrv.2005.02.002. View

14.

Ohto H, Ujiie N, Hirai K . Lack of difference in cytomegalovirus transmission via the transfusion of filtered-irradiated and nonfiltered-irradiated blood to newborn infants in an endemic area. Transfusion. 1999; 39(2):201-5. DOI: 10.1046/j.1537-2995.1999.39299154736.x. View

15.

Hamprecht K, Maschmann J, Vochem M, Dietz K, Speer C, Jahn G . Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet. 2001; 357(9255):513-8. DOI: 10.1016/S0140-6736(00)04043-5. View

16.

Yeager A, Grumet F, Hafleigh E, Arvin A, Bradley J, Prober C . Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr. 1981; 98(2):281-7. DOI: 10.1016/s0022-3476(81)80662-2. View

17.

Ziemann M, Unmack A, Steppat D, Juhl D, Gorg S, Hennig H . The natural course of primary cytomegalovirus infection in blood donors. Vox Sang. 2010; 99(1):24-33. DOI: 10.1111/j.1423-0410.2009.01306.x. View

18.

Slobedman B, Mocarski E . Quantitative analysis of latent human cytomegalovirus. J Virol. 1999; 73(6):4806-12. PMC: 112523. DOI: 10.1128/JVI.73.6.4806-4812.1999. View

19.

Laupacis A, Brown J, Costello B, Delage G, Freedman J, Hume H . Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion. 2001; 41(4):560-9. DOI: 10.1046/j.1537-2995.2001.41040560.x. View